Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ProKidney Corp. (PROK : NSDQ)

• Company Description    ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM, N,C. Number of Employees: 204

• Price / Volume Information    Yesterday's Closing Price: $4.54 Daily Weekly Monthly 20 Day Moving Average: 32,919,478 shares Shares Outstanding: 292.70 (millions) Market Capitalization: $1,328.85 (millions) Beta: 1.26 52 Week High: $7.13 52 Week Low: $0.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 406.70% 389.33% 12 Week 474.03% 384.43% Year To Date 168.64% 187.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2000 FRONTIS PLAZA SUITE 250 - WINSTON-SALEM,NC 27103 USA ph: 336-999-7019 fax: - daniel@lifesciadvisors.com http://www.prokidney.com

• General Corporate Information    Officers Bruce Culleton - Chief Executive Officer and Director Pablo Legorreta - Chairman of the Board and Director James Coulston - Chief Financial Officer William F. Doyle - Director Jennifer Fox - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74291D104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 292.70 Most Recent Split Date: (:1) Beta: 1.26 Market Capitalization: $1,328.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 1.20% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.75% vs. Previous Quarter: 23.53% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 202.63% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -15.03 12/31/24 - -13.58 Current Ratio 06/30/25 - - 03/31/25 - 10.96 12/31/24 - 10.93 Quick Ratio 06/30/25 - - 03/31/25 - 10.96 12/31/24 - 10.93 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -54,267.64 12/31/24 - -215,701.31 Book Value 06/30/25 - - 03/31/25 - -3.41 12/31/24 - -3.41 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©